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Spinalmuscular atrophy (SMA) is a neurodegenerative
disease in humans and the most common genetic
cause of infant mortality. The disease results in motor
neuron loss and skeletal muscle atrophy. Despite a
range of disease phenotypes, SMA is caused by muta-
tions in a single gene, the Survival of Motor Neuron 1
(SMN1) gene. Recent advances have shed light on
functions of the protein product of this gene and the
pathophysiology of the disease, yet, fundamental
questions remain. This review attempts to highlight
some of the recent advances made in the understand-
ing of the disease and how loss of the ubiquitously ex-
pressed survival of motor neurons (SMN) protein re-
sults in the SMA phenotype. Answers to some of the
questions raisedmay ultimately result in a viable treat-
ment for SMA.
Introduction
One of the major challenges facing researchers engaged
in the study of neurodegenerative and neurodevelop-
mental diseases is to explain why defects in ubiquitously
expressed proteins have such a selective effect on the
nervous system and its constituent cell types. Explaining
the molecular mechanisms underlying the disease phe-
notypes has been hampered by their multifactorial na-
ture and high incidence of sporadic cases. Alzheimer’s
disease, Parkinson’s disease, and amyotrophic lateral
sclerosis (ALS) are among the most common neurode-
generative diseases in humans and good examples of
disorders that exemplify these challenges. Two less
common neurological diseases which are monogenic
in origin but are the result of defects in ubiquitously ex-
pressed proteins involved in housekeeping functions
are Rett syndrome and 5q spinal muscular atrophy
(SMA). The former is characterized by mutations in the
gene encoding methyl – CpG binding protein 2 (MeCP2),
which likely regulates gene expression and chromatin
structure; the latter by a deficit of the survival of motor
neurons (SMN) protein, whose best characterized func-
tion is in snRNP biogenesis and pre-mRNA splicing.
Yet, despite the apparent need for these proteins in all
tissues, Rett syndrome, a prototypical neurodevelop-
mental disorder, is characterized by a specific defect in
maintaining proper function of postmitotic neurons in
the forebrain, hippocampus, and brainstem, while SMA
has a particularly profound effect on lower motor neu-
rons. This begs the question: do the proteins implicated
in these diseases have functions in neurons other than
their proposed housekeeping roles? Do they modulate
downstream pathways specific to the tissues affected?
*Correspondence: um2105@columbia.eduAlternatively, are neuronal cells simply more susceptible
than other tissues to genetic, biochemical, and environ-
mental insults? Answering these questions using multi-
factorial diseases as paradigms poses an extra chal-
lenge precisely due to their complicated genetics. An
attractive alternative would therefore be to address
these issues in diseases with a simple Mendelian inheri-
tance pattern. Spinal muscular atrophy provides re-
searchers studying neurodegenerative diseases with
this opportunity. This review highlights why (1) SMA
might be considered a prototypical neurodegenerative
disease in which to address certain general questions
facing the field, and (2) why a thorough understanding
of this disorder might shed light on the mechanisms
that have a specific effect on the development, health,
survival, and causes of motor neuron degeneration,
which ultimately leads to a disease phenotype.
Proximal spinal muscular atrophy, commonly referred
to as SMA, is a common autosomal recessive neuro-
muscular disease that affects the anterior horn cells of
the spinal cord, resulting in atrophy of the proximal
muscles of the limbs and trunk. There are numerous
other forms of spinal muscular atrophy which share cer-
tain characteristics with proximal SMA; however, they
are genetically distinct and often affect different subsets
of neurons and muscle. They include autosomal domi-
nant forms of the disease (Sambuughin et al., 1998;
Van der Vleuten et al., 1998), X-linked forms (La Spada
et al., 1991; Kobayashi et al., 1995), recessive forms
that affect the distal muscles (Viollet et al., 2002), and
a severe form of SMA (SMARD) with respiratory distress
(Grohmann et al., 2001) (Table 1).
After cystic fibrosis, SMA is the most common autoso-
mal recessive disorder in humans, with a carrier fre-
quency of approximately 1 in 35 and therefore an inci-
dence of 1 in 6000 in the human population. It is also
the most common genetic cause of infant mortality. De-
spite the high incidence of the disease in the human pop-
ulation, SMA has gained relatively little attention among
researchers studying neurodegenerative diseases.
However, it has a fascinating biology, which includes
two major players: the highly homologous SMN1 and
SMN2 genes. A splicing defect in SMN2 is a key factor
in causing the disease phenotype, while the SMN pro-
tein, expressed by both genes, is very likely multifunc-
tional. However, low levels of the protein have a particu-
larly detrimental effect on one tissue type, the lower
motor neurons. One of SMN’s functions is essential to
cell survival. These characteristics, coupled with a rela-
tively simple Mendelian inheritance pattern, make a com-
pelling case that study of this disorder in more detail will
provide a prototype that might shed considerable light
on motor neuron biology and disease. Such studies
may eventually lead to a better understanding of SMA
and other similar diseases and may accelerate progress
toward rational therapeutics.
The Genetic Principles of SMA
Identifying the genes involved in SMA was complicated
by the highly complex and unstable nature of the
Neuron
886Table 1. The Different Forms of Human Spinal Atrophy
SMA Type Mode of Inheritance
Gene/Chromosome
Location Phenotype/Disease Symptoms Onset of Disease
Proximal SMAs
1. Type I SMA Autosomal recessive SMN1;5q11.2-13.3 Proximal muscle weakness, patients never
sit unaided; death < 2 years
< 6 months
2. Type II SMA Autosomal recessive SMN1;5q11.2-13.3 Proximal muscle weakness, patients sit
unaided but become wheelchair bound,
develop scoliosis of spine
6–18 months
3. Type III SMA Autosomal recessive SMN1;5q11.2-13.3 Proximal muscle weakness, patients walk
unaided, normal lifespan
> 18 months
Distal SMA Autosomal recessive 11q13 Distal muscle weakness, diaphragmatic
involvement
2 months–20 years
SMARD Autosomal recessive IGHMBP2;11q13.2 Distal lower limb weakness, diaphragmatic
weakness, sensory, autonomic neurons also
affected
1–6 months
X-linked infantile
SMA
X-linked Xp11.3-q11.2 Arthrogryposis, respiratory insufficiency, scoliosis,
chest deformities, loss of anterior horn cells
at birth
SBMA X-linked Androgen Receptor/
Xq11.2-12
Proximal muscle weakness, lower motor
neuron loss, DRG neuron loss, bulbar
involvement
30–50 years
Distal SMA IV Autosomal dominant 7p15 Distal muscles affected, bilateral weakness
in hands, atrophy of thenar eminence and
peroneal muscle
12–36 years
Congenital SMA Autosomal dominant 12q23-24 Arthrogryposis, nonprogressive weakness of
distal muscles of lower limbs; several cases
of affected pelvic girdle and truncal muscles
at birthgenome where they localize and by phenotypes that
range in severity from the very severe (type I) to the inter-
mediate (type II) to the very mild (some type IIIs and type
IV) (Pearn, 1980). However, the genetics of SMA is actu-
ally relatively simple and unique.
Regardless of disease severity, 95% of all patients are
deleted for a gene containing nine exons that localizes
to chromosome 5q11.2-13.3, termed the telomeric sur-
vival of motor neuron gene (SMNT or SMN1). The re-
maining 5% carry small mutations in the gene. SMN1
lies within an inverted duplication, the centromeric half
of which contains an almost identical copy gene,
(SMNC or SMN2) (Lefebvre et al., 1995). The genes dis-
play an unprecedented level of homology that includes
intronic and promoter sequences (Monani et al., 1999).
SMA patients lack SMN1, but they always carry at least
one copy of SMN2, which is only partially functional and
therefore unable to compensate for the lack of the for-
mer. A critical, translationally silent single nucleotide
C / T transition 6bp inside SMN2 exon 7 that pro-
foundly influences splicing (Lorson et al., 1999; Monani
et al., 1999) is responsible for the difference in expres-
sion between the two genes. The single nucleotide tran-
sition also serves to make a genetic diagnosis of SMA in
the vast majority of patients relatively straightforward,
based on a simple PCR reaction (van der Steege et al.,
1995). The PCR reaction distinguishes the nucleotides
from one another and, thus, SMN1 from SMN2. SMA,
therefore, unlike other diseases with simple Mendelian
inheritance patterns, e.g., Duchenne muscular dystro-
phy, cystic fibrosis, and Rett syndrome, is relatively
easy to diagnose genetically. As a consequence of the
nucleotide difference, the major transcript from SMN1
is full length (FL-SMN) and includes all nine exons, while
the major transcript from SMN2, (SMND7), lacks exon 7.
SMN2 does produce the FL-SMN transcript but at rela-
tively low levels (Figure 1). Patients therefore expressonly low levels of the functional FL-SMN protein, the
SMN D7 isoform being unstable and rapidly degraded
(Coovert et al., 1997; Lefebvre et al., 1997). Low levels
of the SMN protein are clearly insufficient for the survival
of motor neurons and result in the disease phenotype.
Due to the unstable nature of the genome that contains
the SMN genes, patients can carry a varying number of
SMN2 genes. The greater the number of SMN2 genes,
the more the FL-SMN protein is expressed, and the
milder the disease phenotype (McAndrew et al., 1997;
Feldkotter et al., 2002). This explains the range of pheno-
types seen in SMA and intuitively makes SMN2 an at-
tractive molecular target in therapeutic strategies.
The Alternative Splicing of the SMN2 Gene
There are currently two prevailing views that provide dif-
ferent explanations as to the mechanism by which the
single nucleotide change between the SMN genes alters
the splicing of exon 7 in the SMN2 gene. Cartegni and
Krainer (2002) provided evidence that the difference
disrupts an exonic splicing enhancer (ESE) in exon 7 to
which the splicing factor ASF/SF2 binds. The efficient
binding of ASF/SF2 to SMN1 exon 7 but not SMN2
exon 7 causes the latter to be skipped, resulting in
w10% of the transcript from the SMN2 gene to be full
length. Kashima and Manley (2003) have provided an al-
ternative explanation in which the same difference in
SMN2 acts to create an exonic splicing silencer (ESS)
to which a splicing repressor, hnRNP A1, binds. Binding
of the repressor to SMN2 exon 7 but not SMN1 exon 7
induces skipping of this exon from a majority of the tran-
scripts from the former gene. Although the mechanisms
differ, the result is the same; i.e., vastly reduced levels of
the FL-SMN transcript from the SMN2 gene. Presently, it
is unclear which of the mechanisms best explains the al-
ternative splicing. It is possible that both contribute to
the skipping of exon 7 from the SMN2 gene. The C/T
transition in SMN2 does not affect expression of this
Review
887Figure 1. The Molecular Basis of Proximal
Spinal Muscular Atrophy Depicting the Two
Major Genes Involved in the Disease, SMN1,
and the Modifier, SMN2
All SMA patients are either homozygously de-
leted for or contain point mutations in SMN1
but always retain at least one copy of the
SMN2 gene. For simplicity, the genes are de-
picted in tandem repeat, although they can
exist in a head-to-head or tail-to-tail configu-
ration. Copy number of the genes can vary
considerably in the population from 1 through
6. ESE, exonic splicing enhancer; ESS, exonic
splicing silencer; FL-SMN, full-length SMN;
yellow box in exon 7 denotes putative ESE/
ESS.gene at the transcriptional level, but the effect on the
level of total SMN protein is profound. Studies have
shown that the SMND7 transcript is translated but is de-
tected only at extremely low levels on Western blots,
presumably because it is quickly degraded. SMN2,
therefore, produces only a fraction of the SMN protein
compared to its telomeric homolog, levels clearly insuf-
ficient for the health and survival of the motor neurons
(Coovert et al., 1997; Lefebvre et al., 1997), and the
loss of which constitutes a key characteristic of the hu-
man disease. In essence, then, SMA results from inade-
quate levels of the FL-SMN protein.
The Biochemistry of the SMN protein in SMA
The FL-SMN protein consists of 294 amino acids and
does not exhibit homology to any previously identified
protein. It migrates as a 38 kDa band on an SDS gel
and is ubiquitously expressed. Particularly high levels
of the protein are found in the spinal motor neurons, ap-
parently the most profoundly affected cells in SMA pa-
tients. Individuals lacking the SMN1 gene express vastly
reduced levels of the protein, but since there is a direct
correlation between SMN2 copy number and SMN pro-
tein levels/disease phenotype, milder patients generally
produce higher levels of the protein than do severely af-
fected ones.
In 1996, a serendipitous observation noted that the
SMN protein is capable of binding heterogeneous nu-
clear ribonucleoproteins (hnRNPs) and localizes to
dot-like structures within HeLa cell nuclei (Liu et al.,
1997). These structures were often found to colocalize
with coiled bodies and were therefore termed gems
(gemini of coiled bodies). Since coiled bodies (Cajal
bodies) are known to be rich in factors involved in the
transcription and processing of many types of nuclear
RNAs, small nuclear ribonucleoproteins (snRNPs), and
small nucleolar ribonucleoproteins (snoRNPs), it was
concluded that SMN probably plays a role in RNA me-
tabolism. This was later confirmed in a series of papers
published by the Dreyfuss and Fischer laboratories
which showed that SMN exists in the cell as part of
a large complex consisting of at least six interacting pro-teins termed gemins 2-7 (Reviewed in Gubitz et al.,
2004). This complex has been postulated to function
as an ‘‘assemblysome’’ that promotes high fidelity and
nonpromiscuous interactions between RNA binding
proteins and their target sequences. In this capacity,
the complex is thought to scrutinize RNAs for specific
features that define them as snRNAs and, thus, allow
the assembly of only the appropriate Sm core proteins
on them in a process called snRNP biogenesis. In a se-
ries of fairly well-defined steps (Yong et al., 2004), the
formation of the SMN-bound snRNP particle in the cyto-
plasm is followed by the particle’s translocation into the
nucleus, where it dissociates with the SMN complex and
concentrates in Cajal bodies. The SMN complex then
engages in pre-mRNA splicing.
The role of SMN in snRNP biogenesis and pre-mRNA
splicing (Pellizzoni et al., 1998; Meister et al., 2000; Han-
nus et al., 2000) has been most extensively documented.
However, numerous other SMN binding partners have
been identified, and SMN has been found in various cel-
lular compartments. It is therefore likely that SMN has
other functions. Many of the SMN binding partners
were identified in yeast two-hybrid screens and include
the snoRNP proteins, fibrillarin (Jones et al., 2001) and
GAR-1; the hnRNPs U, R, and Q (Rossoll et al., 2002);
RNA helicase A; a zinc finger protein, ZPR1 (Gangwani
et al., 2001); the FUSE binding protein (Williams et al.,
2000); profilins (Giesemann et al., 1999); RNA polymer-
ase II (Pellizzoni et al., 2001); p53 (Young et al., 2002a);
the Epstein Barr virus nuclear antigen 2 (Barth et al.,
2003); coilin; and the NS1 protein of minute virus in
mice (Young et al., 2002b). The exact implications of
these interactions remain to be determined. However,
they may shed light on why reduced SMN levels have rel-
atively little impact on cells other than motor neurons in
the human disease.
An interesting characteristic of the SMN protein and
one that has provided an explanation as to why muta-
tions result in reduced levels, is a tendency to form mul-
timeric structures. Studies have shown that there are
two domains responsible for self-association – a minor
one encoded by exon 2 and a major one encoded by
Neuron
888exon 6 (Young et al., 2000; Lorson et al., 1998). The abil-
ity of SMN monomers to oligomerize and form a complex
that includes the integral components of the complex,
gemins 2-7, stabilizes the entire structure (Lorson
et al., 1998; Paushkin et al., 2002). Mutations that disrupt
self-association and the formation of multimeric com-
plexes presumably expose mutant monomers to cellular
degradation, most likely by a ubiquitin ligase-mediated
pathway (Chang et al., 2004). Perhaps it is not surprising
that most mutations in the SMN1 gene that have been
found in SMA patients cluster in close proximity to the
self-association domain in exon 6. It may also not be sur-
prising that mutations in type I patients have the most
severe defects in self-association, while those in type
III patients have a much less profound effect on the abil-
ity of mutant SMN molecules to bind each other.
In addition to being able to self-associate, SMN has
been shown to directly bind Sm proteins, a critical step
in snRNP biogenesis (Liu et al., 1997; Buhler et al.,
1999). Most mutations in the SMN protein disrupt this in-
teraction, suggesting that the disease is a direct conse-
quence of an inability to form and regenerate snRNP par-
ticles. However, there is at least one point mutation,
E134K, and perhaps others (Cusco et al., 2004) that lie
in exons 3 or 4 that may suggest otherwise. Experiments
have shown that the Sm proteins bind the tudor domain
of SMN, a region that spans part of exons 3 and 4 (Se-
lenko et al., 2001), but there is lack of clear agreement
as to whether this is indeed the case. An alternative the-
ory proposes that the Sm proteins bind exon 6 of SMN
(Liu et al., 1997). What is certain is that the E134K muta-
tion in the SMN tudor domain causes a type I SMA phe-
notype. It is critical, therefore, to conclusively and un-
ambiguously determine whether this mutation disrupts
binding of the Sm proteins. If, as suggested, the Sm pro-
teins bind exon 6 and E134K does not affect binding of
these proteins to SMN, it could well be that the SMA phe-
notype is not necessarily a reflection of a defect in snRNP
biogenesis.
The role of SMN in SMA: Two Contrasting Views
Given the important housekeeping role of SMN in snRNP
biogenesis and pre-mRNA splicing, coupled with the
very selective motor neuron disease phenotype in
SMA, two schools of thought have emerged about the
role of this protein in motor neuron degeneration and
muscle atrophy. These divergent views, described be-
low, stem from an expectation that a function as univer-
sal as snRNP biogenesis and pre-mRNA splicing would
affect all tissues equally, and the presentation of the dis-
ease phenotype in SMA patients and animal models,
which clearly affects only a specific subset of tissues –
the motor neurons and muscle. An interesting parallel in-
volves the super-oxide dismutase (SOD-1) gene, the
product of which is also ubiquitously expressed, and
the motor neuron disease amyotrophic lateral sclerosis.
(1) SMA Is a Direct Consequence of a Defect in
snRNP Biogenesis and Pre-mRNA Splicing
The first school of thought postulates that SMA and the
motor neuron phenotype are a direct consequence of
a disruption in SMN’s housekeeping role in snRNP bio-
genesis and pre-mRNA splicing. Moreover, reduced
SMN (Wan et al., 2005) or a mutation in SMN1 (Buhler
et al., 1999) found in SMA patients compromises snRNPassembly and, therefore, spliceosomal activity. One
study that supports the hypothesis that the SMA pheno-
type is due to a specific defect in snRNP biogenesis
found that motor axon defects caused by injecting anti-
sense morpholinos against SMN, gemin 2, and the pro-
tein pICln into zebrafish embryos can be rescued by
coinjecting purified U snRNPs (Winkler et al., 2005). All
three proteins have been implicated in snRNP assembly
(Reviewed in Gubitz et al., 2004; Meister et al., 2001). The
data may be construed as strong evidence linking the
SMA phenotype to inefficient snRNP biogenesis. How-
ever, the extent of rescue varies significantly between
SMN-injected and gemin 2-injected fish. One possible
explanation is that restoring snRNP biogenesis alone
cannot rescue the motor neurons and that SMN has
a second critical function that prevents these cells
from degenerating. Although snRNP assembly is com-
promised when SMN mutations from patients are used
to study this process in vitro, attributing the SMA pheno-
type to SMN’s role in pre-mRNA splicing is somewhat
less clear. In part, this is because conclusions about
the SMA phenotype being a defect in pre-mRNA splicing
are based (1) on the use of a dominant-negative muta-
tion that has never been found in patients but which
does inhibit splicing in vitro; (2) the absence of such an
effect when an antibody to the C terminus of SMN, pre-
sumed to disrupt oligomerization, is used in the splicing
assays; and (3) lack of an adverse effect on pre-mRNA
splicing using mutations commonly found in SMA
patients (Pellizzoni et al., 1998). In order to explain the
tissue-specific nature of SMA, this view proposes that
affected motor neurons, being large, high-energy-
requiring cells, simply have a lower tolerance for de-
pleted SMN levels and are, therefore, uniquely sensitive
to loss of the SMN1 gene, compromised snRNP as-
sembly, and inefficient pre-mRNA splicing. However,
a lack of an adverse effect on other large, high-energy-
requiring cells, such as cortical motor neurons and sen-
sory neurons in SMA, makes this a questionable ex-
planation. It is possible that the unique sensitivity of
affected motor neurons in SMA is a result of aberrant
splicing of one or more RNAs critical to the appropriate
functioning of these cells. However, such RNAs have yet
to be identified.
(2) SMA Is a Consequence of a Motor Neuron-
Specific Function of the SMN Protein
A second school of thought emerged from observations
demonstrating the accumulation of the SMN protein in
the axons and growth cones of neuron-like cells in vitro
(Fan and Simard, 2002) and anterior horn cells in vivo
(Tizzano et al., 1998). These observations have been bol-
stered by experiments identifying the presence of SMN-
containing granules within the neurites of chick cortical
neurons and rat spinal motor neurons (Figure 2) that as-
sociate with microtubules and exhibit bidirectional
movement between the cell body and the growth cone
(Zhang et al., 2003). These particles are RNP particles
and suggest a specific role for the protein in neuronal
cells and, perhaps, an even more specific one in motor
neurons. It is now fairly well-established that SMN can
bind RNA (Lorson and Androphy, 1998; Bertrandy
et al., 1999) and ribonucleoprotein particles (Jones
et al., 2001; Liu and Dreyfuss, 1996; Mourelatos et al.,
2001). In addition to being a constituent of snRNPs,
Review
889Figure 2. A chick cortical neuron stained with
an antibody against SMN showing abundant
nucleocytoplasmic staining as well as the
presence of granules (arrows) within neurites
and the growth cone. The granules, RNP par-
ticles, are found associated with microtu-
bules, indicating movement along the axon,
and supports the idea of a motor neuron spe-
cific function of the SMN protein (also see
Zhang et al., 2003)SMN may well be a constituent of a different RNP com-
plex that in motor axons is capable of transporting spe-
cific RNAs to the growth cone in response to local cues
during development. Data indicating a specific interac-
tion between SMN and b-actin mRNA mediated by the
protein hnRNP-R lends support to this idea (Rossoll
et al., 2003). Reduced growth cone size, b-actin levels,
and shorter neurites in primary motor neurons from
SMA mice adds further weight to this line of thought.
The idea of proteins involved not just in mRNA localiza-
tion but also in regulating translation in neurites is not
new. Both FMRP, the defective protein in Fragile X men-
tal retardation syndrome, and the cytoplasmic polyA el-
ement binding protein have been implicated in these
roles (Bassell and Kelic, 2004). SMN may have a similar
role in motor neurons, thus, explaining the specific de-
fect characteristic of the disease phenotype. Further
work on the identification of specific RNAs associated
with SMN granules in growth cones as well as studies
examining whether SMN associates with poly-ribo-
somes in axons will be required to test this hypothesis.
Animal Models of SMA
Animal models can shed considerable light on the path-
ogenesis and mechanisms of their respective human
diseases. This has been the case in SMA. Since the
SMN genes were first identified, numerous organisms
have been manipulated in order to generate animal
models of the disease (Table 2). However, given the
fact that humans are the only species with an SMN2
gene and that the SMN protein is involved in a house-
keeping function in cell survival, this has not been a par-
ticularly straightforward endeavor.
Perhaps the most pertinent of the animal models of
SMA and those most likely to provide answers to the
many remaining questions facing researchers studying
the human disease are the murine models. Several
mouse models of SMA have been generated in the last
five years. These have involved basically two ap-
proaches, both dictated by the presence of only one
SMN gene in mice, murine Smn, which is the equivalent
of human SMN1 and results in an embryonic lethal phe-
notype when homozygously deleted (Schrank et al.,
1997).
To circumvent this problem, the Melki laboratory se-
lectively and completely deleted FL-SMN in all neurons
expressing a Cre recombinase under the neuron-spe-
cific enolase promoter. In what is described as the ‘‘neu-
ronal’’ mutant, mice displayed motor abnormalities and
signs of skeletal muscle denervation and succumbed tothe disease at a mean age of 25 days (Frugier et al.,
2000). These mice display a significantly larger loss of
motor axons than of cell bodies, exhibit a massive accu-
mulation of neurofilaments in terminal axons, and fail to
show signs of axonal sprouting (Cifuentes-Diaz et al.,
2002). The pathology described was construed to indi-
cate a dying back axonopathy in SMA. Since muscle at-
rophy is a key characteristic of human spinal muscular
atrophy, the Melki lab also selectively and completely
deleted Smn in mature myofibers, resulting in what
they termed a severe ‘‘muscular’’ mutant (Cifuentes-
Diaz et al., 2001). Although the dystrophic phenotype in-
cluding necrotic muscle elevated creatine kinase and
a mean lifespan of 33 days was unexpected, in retro-
spect it is not completely surprising, given Smn’s house-
keeping function in snRNP biogenesis and pre-mRNA
splicing. In fact, knocking out SMN in any cell would
be detrimental to its survival, as was demonstrated sub-
sequently in mice in which the protein was selectively
deleted in liver (Vitte et al., 2004). In an extension of
the muscle study, an increase in SMN levels by 50% in
muscle satellite cells resulted in a much milder pheno-
type, termed a ‘‘mild’’ muscular phenotype (Nicole
et al., 2003). These mice live considerably longer (w8
months), reportedly due to the regenerative capacity of
satellite cells, homozygously intact for murine Smn, to
form new muscle. These studies, in addition to in vitro
work involving nerve-muscle cocultures (Guettier-
Sigrist et al., 1998), have argued for a role for SMN in
muscle in preventing the SMA phenotype and, thus, for
targeting muscle as a therapeutic strategy in SMA.
The second approach that was used to create mouse
models of SMA involved introducing the SMN2 gene
onto the Smn2/2 genetic background either alone (Mo-
nani et al., 2000) or in the form of a BAC clone (Hsieh-
Li et al., 2000) containing SMN2, the SERF1 gene, and
part of a neighboring gene, the neuronal apoptosis in-
hibitory protein (NAIP). Both strategies showed that
the phenotype depends on the SMN2 transgene copy
number and closely mimics the human disease condi-
tion wherein all patients carry at least one SMN2 gene.
Expressing SMND7, the major product of the SMN2
gene, on a type I SMA genetic background alleviates
the disease phenotype, arguing for limited ability of the
mutant protein to function. An A2G missense mutation
expressed in type I SMA mice generates a mild mouse
model of SMA. Severe SMA (SMN2;Smn2/2) mice carry-
ing two copies of the SMN2 transgene are phenotypi-
cally indistinguishable from their littermates at P0. By
P3 they are visibly smaller and weaker, stop suckling
Neuron
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Organism Manipulated Type of Manipulation Phenotypic Characteristics of Disease
S. pombe Deletion (null allele) Cells not viable
Overexpression of wild-type allele Increase in growth rate; viability not compromised
Overexpression of deletion alleles Dominant-negative phenotype; growth/viability compromised;
missense mutations cause mislocalization of protein to cytoplasm
C. elegans Knockdown of wild-type allele with RNAi Variable phenotype in progeny ranging from embryonic lethality
to multiple, severe early developmental defects
Over-expression Embryonic viability compromised in progeny
D. melanogaster Spontaneously occurring missense
mutation
Late larval lethality; mutant larvae display loss of mobility, excitatory
post-synaptic currents reduced; abnormal clustering of GluR
subunits at NMJ
D. rerio Knockdown of fish smn using anti-sense
morpholinos
Embryonic lethality between late gastrulation and early
somitogenesis; motor axon outgrowth and pathfinding defects
M. musculus Homozygous knockout of Smn Smn-/-/Embryonic lethality before implantation
Cre-loxP deletion of Smn in neurons Smn D7/F7;NSE-Cre/Profound motor axon but not cell body loss;
muscle atrophy of neurogenic origin; death at 4 weeks
Cre-loxP deletion of Smn in muscle Smn D7/F7;HSA-Cre/ Muscular dystrophy; death atw33 days in
‘‘severe’’ muscular mutants; similar pathology but increased survival
in ‘‘mild’’ muscular mutants (SmnF7/F7; HSA-Cre) tow8 months
Complementation of mouse Smn knockout
with varying copies of human SMN2 and
mutant SMN transgenes
1–2 copy SMN2;Smn-/- mice/ type I SMA phenotype death
between 1 and 8 days
SMN2+/+;D7+/+;Smn-/- mice/ severe type II phenotype death
between 10 and 16 days
SMN2+/-;SMN A2G+/-;Smn-/-/ type III SMA phenotype
deathw6 months
8-16 SMN2;Smn-/- mice/ complete phenotypic rescue
All SMA mice display motor neuron degeneration, muscle weakness
and have reduced SMN protein levels
Note: Smn D7/F7 denotes mice carrying one deletion allele (D7) and one floxed exon 7 allele that can be deleted by expression of the Cre protein;
NSE, neuron specific enolase; HSA, human a skeletal actin.at wP4, and death occurs on average between P5 and
P6. Motor neuron cell body loss is not apparent in severe
SMA mice at P1, but by P5 between 30% and 40% of the
spinal and facial motor neurons have degenerated, the
animals stop suckling, presumably due to weakness in
muscles controlling swallowing and suckling, and are
unable to right themselves when placed on their sides.
A similar, albeit milder, phenotype is seen in mice carry-
ing the SMND7 transgene (Le et al., 2005). No abnormal-
ities in the dystrophin-associated complex were seen in
the muscle of these mice, suggesting that SMA does not
involve a dystrophic phenotype. On the other hand,
there is clear evidence of denervated NMJs and reduced
acetylcholine receptor (AChR) clusters. Mice carrying an
A2G missense mutation (Monani et al., 2003) display
classic signs of type III SMA, including delayed motor
neuron degeneration (Figure 3), EMG abnormalities,
and axonal sprouting. Although it has been adequately
demonstrated that these mice represent accurate mod-
els of the range of disease phenotype seen in human
SMA, there remains a wealth of information to be
gleaned from them about the details of the pathophysi-
ology of this disease.
In addition to using the mouse to model human SMA,
a number of other organisms including invertebrates
have been utilized. These too lack the SMN2 gene and,
therefore, may be somewhat limited in the way they
mimic the human disease. Indeed, in some cases, the
phenotypes seen in the mutant animals are also rather
confusing. In the nematode C. elegans, expression of
mutant SMN protein or overexpressing the normal pro-
tein seems not to affect the particular animal in which
the manipulation is carried out, but rather its offspring,in which it is generally embryonic lethal (Miguel-Aliaga
et al., 1999). In Drosophila, a knockout of the SMN
ortholog results in viable larvae but only due to a large
maternal contribution of the protein, which consistently
declines until death at late larval stages (Chan et al.,
2003). Although these animals do exhibit a neuromuscu-
lar phenotype and suggest that SMN is important in
muscle, it is unclear whether death ultimately occurs
due to developmental arrest when maternal SMN is
completely depleted and a failure of the imaginal discs
to form adult structures.
In the zebrafish Danio rerio, the human disease condi-
tion was modeled by using anti-sense morpholino tech-
nology to reduce SMN levels to those presumably found
in SMA patients (McWhorter et al., 2003). In a striking
finding, it was observed that a knockdown of the SMN
protein systemically caused pathfinding defects in mo-
tor axons. This involved truncations and premature
branching at the growth cone. Furthermore, by knocking
down SMN in motor neurons alone, the effect was found
to be cell autonomous, having no effect on muscle de-
velopment. This adds considerable support to a specific
role for SMN in motor neurons and makes a strong argu-
ment for SMA being a neurodevelopmental defect. Al-
though interesting, the finding is inconsistent with
observations made in presymptomatic human SMA
patients who have normal numbers of motor units, as
assessed electrophysiologically by motor unit number
estimation (MUNE) analysis (Bromberg and Swoboda,
2002). The latter observation argues for appropriate
nerve-muscle connections to be made during develop-
ment and instead suggests that SMA is not a defect
in motor neuron development, but rather a problem
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Mice
(A) Cresyl-echt violet section of lumbar spinal
motor neurons (arrows) in a 3-month-old type
III SMA mouse and its normal littermate,
showing reduced cells in the former.
(B) Quantification of lumbar spinal motor neu-
rons and motor neurons of the facial nucleus
in SMA III and normal mice (n = 3 in each
case).that may involve synaptic maintenance. At least two ex-
planations could account for these apparently conflict-
ing observations. First, the inability to exercise fine con-
trol of SMN levels using anti-sense morpholinos in fish
resulting in correspondingly more or less severe pheno-
types, and, second, a fundamental difference in neuro-
nal development in fish and man. Findings in the fish
will have to confirmed or countered in murine models
of SMA.
While data from the animal models described above
have certainly provided us with important clues about
spinal muscular atrophy, they have also raised a number
of additional questions. Answers to these will be critical
in translating basic science findings into therapeutic
strategies. The most pressing of these include: why
does a ubiquitously expressed protein cause a motor
neuron disease, and why do defects in the SMN protein
fail to have such profound effect on other tissues? A re-
lated question is what is the primary target of the dis-
ease and is there is a specific compartment of the cell
type most affected in SMA, where a critical level of
SMN protein is required to prevent the disease pheno-
type? Assuming motor neurons are the primary target
of the disease, one strategy to address the latter half
of the question would be to separate SMN’s role in
snRNP biogenesis/pre-mRNA splicing from other pre-
sumed functions of the protein by selectively targeting
SMN to axons or the cell body. Although the tissues
most affected are the motor neurons and muscle, it is
feasible that reduced SMN levels contribute to the dis-
ease phenotype by also affecting peripheral schwann
cells (PSCs) or glia. In this respect, it is worth noting
the important role PSCs play in the development and
maintenance of NMJs and in nerve sprouting/regenera-
tion (Koirala et al., 2003). In light of this and important in-
sights into the pathogenesis of ALS from chimeric mice
carrying a mixture of wild-type and SOD-1 expressing
neuronal and nonneuronal cells (Clement et al., 2003),
it may be interesting to determine the effect of normalnonneuronal cells on SMA motor neurons. Second,
why are certain motor neurons and therefore certain
muscles affected in this disease more profoundly than
others? This implies a differential effect of low SMN lev-
els on a particular subset of motor neurons. It may well
be that these motor neurons simply constitute a larger
motor unit than those that innervate fewer muscle fibers.
Motor neurons that form large motor units may be selec-
tively vulnerable to decreased SMN levels, particularly if
the critical function of the protein in these cells requires
it to be transported to the growth cones. In this regard, it
may be worth noting that it is not even clear whether dis-
tal muscles are really spared in SMA. MUNE studies in
humans carried out primarily on the ulnar nerve, which
innervates the hypothenar muscle group, suggest that
SMA is not restricted to atrophy of the proximal muscles
(Bromberg and Swoboda, 2002). Third, is SMA a neuro-
developmental disease and, if so, how early during de-
velopment are the motor neurons/muscle affected?
One possibility is that nerves do make contact with mus-
cle but the connections are simply not functional. This
would likely require a detailed study of the NMJ includ-
ing electrophysiological experiments. Equally important
is to determine whether the disease affects only the an-
terior horn cells or whether it involves a defect in synap-
togenesis/synaptic maintenance between Ia afferents
and these cells. 5) Finally, it would be of interest, from
a therapeutics standpoint, how early during the course
of the disease normal SMN levels would have to be re-
stored to affected motor neurons before they are irre-
versibly damaged. These experiments may be extended
to answer a related question, i.e., do high levels of the
SMN protein need to be maintained at all times in the
relevant critical tissues or is there a window of time
during development when there is an increased require-
ment for SMN?
An answer to the last question may already be avail-
able based on the expression profile of the SMN genes
during development. Numerous studies have indicated
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ment and drop sharply by postnatal day 7. It is quite
likely that this period defines when a minimum level of
SMN must be maintained in order to ensure the health
and normal development of motor neurons. A subse-
quent decrease in SMN levels, particularly during adult
life, may be quite compatible with a disease-free pheno-
type despite a significant loss of motor neurons. A case
in point is 12-month-old Smn+/2 mice that display no
overt motor neuron disease phenotype despite a 50%
loss of their spinal motor neurons (Jablonka et al., 2000).
Possible Therapeutic Strategies in SMA and Future
Prospects
Since the SMN genes were first cloned, much has been
learned about the biology of SMA. Based on the collec-
tive findings of researchers in the field, one can begin to
explore ways of treating this disease. Currently the most
promising, although by no means only, strategies are as
follows.
(1) Targeting the SMN2 Gene
The correlation between SMA phenotype and SMN2
copy number in SMA patients and the demonstration
that sufficient SMN protein from SMN2 in transgenic
mice can completely ameliorate the disease (Monani
et al., 2000) has made this gene an obvious target that
can be modulated in therapeutic strategies. In the last
four years, a number of compounds, many of them his-
tone deacetylase (HDAC) inhibitors, have been shown
to upregulate SMN protein from the SMN2 gene by acti-
vating its promoter (Chang et al., 2001; Sumner et al.,
2003; Brichta et al., 2003; Grzeschik et al., 2005). One
such compound, phenylbutyrate, has already been
tested in humans and shown to increase FL-SMN RNA
from SMN2, although whether this translates into in-
creased SMN protein remains to be determined (Brahe
et al., 2005). HDACs are often nonspecific and known
to affect expression of w2% of all known genes by
opening up the chromatin structure of DNA and, thus,
making it accessible to the transcriptional machinery
of the cell. One report provides a mechanistic explana-
tion for the effect of HDAC inhibitors on the SMN2
gene. Treatment with one such compound, valproic
acid (VPA), resulted in an increase in acetylated histones
in the upstream promoter region of the SMN2 gene that
correlated with a 2-fold increase in promoter activity
(Kernochan et al., 2005).
An increase in SMN protein from SMN2 can also be
achieved by altering its splicing to increase levels of
the FL-SMN transcript. Small molecules (Andreassi
et al., 2001) as well as the use of reagents such as pep-
tide nucleic acids (PNAs) have been shown to effect this
increase in cell culture (Cartegni and Krainer, 2003;
Skordis et al., 2003). Precise mechanisms of action of
these compounds have yet to be defined, but it is possi-
ble that they act indirectly by altering the activity of ser-
ine-arginine (SR) proteins which influence the inclusion/
exclusion of exons into gene transcripts.
A third approach stems from the fact that the major
product of the SMN2 gene is the SMND7 isoform. The
SMND7 protein is unstable but is clearly at least partially
functional, since it is able to increase survival when over-
expressed in severe SMA SMN2;Smn2/2 mice. Studies
suggest that the SMND7 isoform can be stabilized byusing the aminoglycosides tobramycin and amikacin,
which are thought to suppress recognition of the first
naturally occurring translational stop codon in exon 8
of the SMN mRNA and force read through. In tissue cul-
ture assays, the modified protein resulted in increased
SMN levels in fibroblasts from SMA patients, providing
proof of principle of such a strategy (Wolstencroft
et al., 2005). The study will have to be validated in whole
organisms, but it is similar in concept to an approach
used to treat a mouse model of Duchenne muscular
dystrophy that harbors a nonsense mutation in the dys-
trophin gene with the aminoglycoside gentamycin
(Barton-Davis et al., 1999).
Although the strategies described above are clearly
capable of increasing SMN in cell culture assays, it is
not clear how well the compounds tested will work in
whole organisms. The next and most obvious step
would therefore be to validate these strategies in SMA
mice. These experiments are currently underway, al-
though concrete results have yet to be made available.
Despite the lack of this information, there is a pressing
need to treat patients, and clinical trials using FDA-
approved HDAC inhibitors have begun.
(2) Modulating Non-SMN Targets
While considerable attention has been focused on the
SMN2 gene, the identification of patients with similar
5q haplotypes but different disease phenotypes clearly
points to modifiers outside the SMA locus (Prior et al.,
2004). This provides the opportunity to identify addi-
tional targets that might be modulated in treating SMA.
To this end, it would be useful to carry out whole ge-
nome suppressor/modifier screens in tractable organ-
isms such as worms, flies, and fish deficient in SMN pro-
tein and displaying an SMA phenotype. This strategy
may be particularly promising given a recent report
that suggests that two of the members of the SMN com-
plex, gemins 2 and 6, can modulate SMN complex activ-
ity and may therefore be candidates for modulation in
SMA therapies (Feng et al., 2005). If one or both of these
genes can be upregulated to increase SMN activity, par-
ticularly in the motor neurons, it is possible the effect will
be of therapeutic value.
3) Gene Therapy in SMA
Although the use of small molecules to upregulate SMN
protein in patients seems presently to be the most at-
tractive approach as a therapeutic means to treat
SMA, there are other opportunities as well that need to
be explored. Gene therapy may be one alternative ap-
proach. In one report, SMN delivered to motor neurons
using a lentiviral vector had a modestly beneficial effect
in type II SMA mice (Azzouz et al., 2004). In combination
with other molecules such as neurotrophic factors, the
effect may be yet further enhanced, although the key
challenge here will be the efficiency with which the vec-
tors can deliver their cargo to their targets. One neuro-
trophic factor that has been tested is cardiotrophin-1,
a member of the IL-6 cytokine family, that has a benefi-
cial effect on the ‘‘neuronal’’ mouse model of SMA when
administered intramuscularly in an adeno-associated
vector (Lesbordes et al., 2003).
4) Stem Cell Therapy
Stem cells provide a fourth approach. Stem cell therapy
has gained considerable attention for the treatment
of Parkinson’s and Alzheimer’s diseases but poses
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lost cells in spinal motor neuron diseases such as ALS
and SMA. A major problem is to get these cells to differ-
entiate into the appropriate cell type and induce them to
exit the spinal cord to make contact with muscle. A more
feasible approach would be to use stem cells to provide
trophic support and protect surviving motor neurons
rather than to replace lost ones as has been demon-
strated in a rat model of motor neuron degeneration
(Kerr et al., 2003). Since muscle is also affected in SMA
and the phenotype critically dependent on muscle atro-
phy, stem cells may be used to prevent muscle atrophy
or replace lost muscle. A strong argument has been
made for this approach based on work showing that in-
tact satellite cells greatly improve survival in a ‘‘muscu-
lar’’ mouse model of SMA and nerve-muscle coculture
studies indicating a deleterious effect of SMA muscle
on the coculture (Guettier-Sigrist et al., 1998). Along
these lines, arguments have also been made to prevent
muscle atrophy by blocking ubiquitin ligases suppos-
edly involved in this process and/or by causing hyper-
trophy of muscle using agents such as IGF-1 or myosta-
tin delivered directly to muscle. However, one caveat
associated with these strategies is that if SMA is a dis-
ease of muscle and nerve, attempting to rescue one
without a concomitant rescue of the other will not pro-
vide long-term benefits. In fact, an unpublished study
has already shown that expressing SMN in muscle tis-
sue of type I SMA mice has no beneficial effect at all
(A. Burghes and T. Gavrilina, personal communication).
Ultimately, an effective treatment for SMA will proba-
bly depend greatly on what we learn about the function
of the SMN protein in motor neurons and the pathophys-
iology of the disease in animal models. Experiments to
answer many of these questions are already underway
and will, no doubt, contribute significantly to our under-
standing of the disease, not just from a basic science
standpoint, but also in the quest to find a treatment for
this devastating neurodegenerative disease.
Conclusions
In conclusion, it is obvious that significant challenges re-
main toward an eventual treatment for SMA. These stem
from the many unanswered questions this review has
raised. Readers may come away thinking that SMA re-
search is still in its infancy. However, it should be noted
that the tools to answer these questions, i.e., an excel-
lent set of animal models and a basic understanding of
the disease, already exist. It should also be reiterated
that there are a number of compelling reasons investiga-
tors outside the field may find problems in SMA an at-
tractive challenge to take on; for example, SMA is a
neurodegenerative disease in which a defect in a ubiqui-
tously expressed protein affects a very specific tissue
type. The genetics of the disease are also relatively sim-
ple: SMA is autosomal recessive and involves a loss of
function in an essential protein in certain cells. In es-
sence, SMA results from an insufficient amount of the
SMN protein. Furthermore, there is an almost perfect
correlation between disease severity and SMN protein
levels. A fascinating biology, not the least of which in-
volves a splicing defect in the copy gene SMN2, is yet
another reason to recruit new investigators into the field.The presence of the SMN2 gene in all patients imme-
diately provides an obvious target that may be modu-
lated in order to develop therapeutic strategies. In this
respect, SMA is different from a number of other com-
mon Mendelian diseases such as Rett syndrome, cystic
fibrosis, and Duchenne muscular dystrophy, wherein
a loss of function due to mutations in a single gene often
require the reintroduction of the native protein, a chal-
lenge that researchers have been confronted with for
decades. In SMA, the problem of delivery may not exist
if therapies involving the upregulation of the SMN2 gene
are formulated. Furthermore, the relatively high inci-
dence of the disease and the unexpectedly low attention
it has gained provides researchers studying related as-
pects of neurodegeneration with an opportune moment
to apply their expertise to address some of the unan-
swered questions about SMA. One therefore finds it
heartening that NIH has recently placed a special em-
phasis on finding a cure for SMA in the form of requests
for applications under the aegis Project SMA dedicated
to translating basic findings into a clinical treatment.
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